Company Presentation • 17 Aug 2026 20:30
Study update
Company Presentation • 27 Jul 2026 20:00
M&A announcement
Company Presentation • 23 Jul 2026 20:30
Q2 2026
No more presentations
𝛼SK or SearchENTITY
argenx (ARGX BB)
argenx (ARGX BB)
1
Analysis
Health Care • Netherlands
argenx is a global immunology company focused on developing and commercializing antibody-based medicines for severe autoimmune diseases. Its flagship product, VYVGART (efgartigimod), is approved for generalized myasthenia gravis (gMG), immune thrombocytopenia (ITP), and chronic inflammatory demyelinating polyneuropathy (CIDP). The company is headquartered in Amsterdam, the Netherlands, and was founded in 2008.
morex